Literature DB >> 69876

Liver damage from long-term methyltestosterone.

D Westaby, S J Ogle, F J Paradinas, J B Randell, I M Murray-Lyon.   

Abstract

Of 60 patients (42 female transsexuals and 18 impotent males) receiving long-term therapy with methyltestosterone 50 mg three times a day, 19 had abnormal liver-function tests and 33 out of 52 had abnormal liver scans, particularly those who had been treated for more than a year. Liver biopsy specimens showed accumulation of hepatocytes in the liver cords and within the walls of centrilobular veins, and early peliosis hepatis. One patient had a hepatic adenoma. Of the androgens, only 17alpha-alkylated steroids seem to be implicated in the development of cholestatic jaundice, peliosis hepatis, and liver tumours.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69876

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

Review 1.  The evaluation and management of testosterone deficiency: the new frontier in urology and men's health.

Authors:  William P Conners; Abraham Morgentaler
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

2.  The androgen-deficient aging male: current treatment options.

Authors:  J Lisa Tenover
Journal:  Rev Urol       Date:  2003

Review 3.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 4.  When and when not to use testosterone for palliation in cancer care.

Authors:  Rony Dev; Eduardo Bruera; Egidio Del Fabbro
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

Review 5.  Epidemiological and policy issues in the measurement of the long term health effects of anabolic-androgenic steroids.

Authors:  C E Yesalis; J E Wright; M S Bahrke
Journal:  Sports Med       Date:  1989-09       Impact factor: 11.136

6.  Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.

Authors:  Ada Lee; Katya Rubinow; Richard V Clark; Ralph B Caricofe; Mark A Bush; Hui Zhi; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2011-08-25

7.  Peliosis hepatis in recipients of renal transplants.

Authors:  C Degott; B Rueff; H Kreis; A Duboust; F Potet; J P Benhamou
Journal:  Gut       Date:  1978-08       Impact factor: 23.059

Review 8.  Androgen replacement in men with hypogonadism and erectile dysfunction.

Authors:  Marion Albrecht-Betancourt; Rabih A Hijazi; Glenn R Cunningham
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

9.  Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males.

Authors:  Z Chik; A Johnston; A T Tucker; S L Chew; L Michaels; C A S Alam
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.